Animerra

Biotechnology

Overview

Next-GenerationVeterinary Biologics Animerra combines a novel discovery platform with next-generation protein modalities to unlock targets that have been out of reach — bringing a new class of therapeutics to companion animals.

Funding and backers

Total raised
$6.5M
1 round on record
Latest round
$6.5M
Venture round · Jan 2025 · 21 mo ago
Team
11-50
employees, estimated range
The money's age
Due for its next round
21 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 17, 2025 Raised a round Venture round $6.5M · SEC Form D 2024 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jan 2025 $6.5M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Animerra, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Anna RathExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
SOSV
backs Prolific Machines
Madrona Venture Group
backs Archon
RA Capital Management
backs Synolo
Draper Associates
backs LYRIC BIO
BlueYard Capital
backs corintis
SICTIC
backs Embion Technologies SA
Similar startupsby what they do, their industry and backers
SynoloFounded 2023 · 1-10 employees
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.
FlexaVenture round $14.1M · 8 yr ago · Founded 2018 · 51-200 employees
Flexa helps companies of all sizes grow and reach new customers using next-generation payments and loyalty solutions.
AskVet
Data & AI Will Transform the Delivery of Wellness Care and Commerce for Livestock and Companion Animals. Hypercharge Your Sales & Marketing…
corintisVenture round $24M · 13 mo ago · 51-200 employees
We’re building 10× better chip-cooling to unlock the next 100× better computer.
Archon
Antibodies Transformed. A revolutionary class of computationally designed biologics engineered to unlock challenging pathways and better…
Prolific MachinesSeries B $55M · 2 yr ago · Founded 2020 · 51-200 employees · 9 roles
Difficult protein production made simple. A next-generation expression system for next-generation therapeutics.

Financials

Total raised
$6.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $6.5M Details

People

Anna Rath
Executive Officer
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston United States
HQ
10-50 est. staff